Drug Profile
Research programme: histone deacetylase inhibitors - Roche/Takeda San Diego
Alternative Names: 383994; Histone deacetylase inhibitors research programme - Roche/Syrrx; Research programme: HDAC inhibitors - Roche/SyrrxLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Roche; Takeda San Diego
- Class
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 01 Mar 2005 Syrrx has been acquired by Takeda
- 17 May 2004 Preclinical trials in Cancer in USA (unspecified route)